Navigation Links
Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
Date:8/7/2014

SAN DIEGO, Aug. 7, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 2:30 p.m. Eastern time at The InterContinental Hotel in Boston.

Interested parties can access a live audio webcast and slide presentation on the Mast Therapeutics web site at www.masttherapeutics.com. An archived presentation will be available on the web site for 30 days.

About Mast Therapeutics

Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. 

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease, and in a phase 2 clinical study to evaluate whether MST-188 improves the effectiveness of recombinant tissue plasminogen activator therapy in patients with acute limb ischemia. The Company also is developing MST-188 in heart failure and plans to announce its clinical development plans in this indication in the second half of 2014. More information can be found on the Company's web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements

Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, the timing of announcement of clinical development plans for MST-188 in heart failure. Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: delays in the commencement or completion of clinical studies and the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of any planned clinical study; the potential that, even if clinical studies of a product candidate in one indication are successful, clinical studies in another indication may not be successful; the Company's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of its product candidates, including clinical studies, and regulatory activities, and that such third parties may fail to perform as expected; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner its product candidates at inopportune times or pursue less expensive but higher-risk and/or lower return development paths if it is unable to raise sufficient additional capital as needed; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law. 

Logo - http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a


'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014
2. PTC Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
3. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
4. Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
5. PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
7. Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
8. Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
9. Abide Therapeutics Appoints Nancy Thornberry to Board of Directors
10. PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results
11. Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
(Date:6/2/2017)... Mass. , June 2, 2017  NxStage Medical, ... renal care, today announced new findings demonstrating positive biochemical ... ® System One™. The data will be presented ... in Madrid, Spain . ... to Improve Home Dialysis Network in Europe ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... The parent company ... in employee engagement. Omaha-based C&A Industries, a national leader in staffing and ... in North America for 2017. The annual award, issued by Achievers, ...
(Date:6/28/2017)... Church, VA (PRWEB) , ... June 28, 2017 , ... ... http://www.fdanews.com/fdaeumdregs      , No matter on which side of the Atlantic devicemakers ... medical device regulations they have to follow. , In addition to the full text ...
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the highest mortality ... at least one person dies as a direct result from an eating disorder in ... qualified treatment providers. The iaedp Foundation meets this challenge by offering what has become ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces the participation of ... winning television series, scheduled to broadcast fourth quarter 2017. American Farmer airs Tuesdays at ... supplier of garden pea seed. As demand grew, the small company located in Moscow, ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... insurance management and financial planning assistance to clients in southern Montana, is announcing ... offered by Zoo Montana. , The outreach programs offered by Zoo Montana provide ...
Breaking Medicine News(10 mins):